Stockscreener 앱 받기
115.48
0.47%
-0.54
시간 외 거래:
115.48
전일 마감가:
$116.02
열려 있는:
$115.22
하루 거래량:
334.87K
Relative Volume:
0.43
시가총액:
$7.95B
수익:
$217.17M
순이익/손실:
$-202.68M
주가수익비율:
-50.15
EPS:
-2.3028
순현금흐름:
$-156.63M
1주 성능:
-0.13%
1개월 성능:
+5.02%
6개월 성능:
+17.75%
1년 성능:
+19.69%
1일 변동 폭
$113.66
$117.33
1주일 범위
$111.42
$119.75
52주 변동 폭
$74.50
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
명칭
Rhythm Pharmaceuticals Inc
전화
857-264-4280
주소
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
115.48 | 8.10B | 217.17M | -202.68M | -156.63M | -2.3028 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-19 | 개시 | RBC Capital Mkts | Outperform |
| 2025-11-25 | 개시 | Citigroup | Buy |
| 2025-11-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-07-07 | 개시 | Leerink Partners | Outperform |
| 2025-04-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-05 | 재개 | Stifel | Buy |
| 2025-01-02 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Oppenheimer | Outperform |
| 2024-10-21 | 개시 | Guggenheim | Buy |
| 2024-09-18 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-08-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 재확인 | Needham | Buy |
| 2022-03-02 | 재개 | Stifel | Buy |
| 2022-02-17 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 재개 | Goldman | Neutral |
| 2021-08-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-08-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-01-08 | 개시 | Goldman | Sell |
| 2019-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2019-07-08 | 개시 | Canaccord Genuity | Buy |
| 2019-03-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-09-07 | 재개 | Morgan Stanley | Overweight |
| 2018-06-25 | 재확인 | Needham | Buy |
| 2018-06-15 | 재확인 | Needham | Buy |
| 2017-10-30 | 개시 | BofA/Merrill | Buy |
| 2017-10-30 | 개시 | Needham | Buy |
모두보기
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – DUS:1RV - TradingView
Rhythm Pharmaceuticals(RYTM.US) Officer Sells US$8.9 Million in Common Stock - moomoo.com
Rhythm Pharmaceuticals EVP Mazabraud sells $6.6m in stock By Investing.com - Investing.com Nigeria
Rhythm Pharmaceuticals EVP Jennifer Kayden Lee Executes Stock Options and Sells Shares Under 10b5-1 Plan - Kalkine Media
Rhythm Pharmaceuticals EVP Yann Mazabraud Executes Stock Option and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Yann Mazabraud Sells 57,000 Shares - marketbeat.com
Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Sells 75,834 Shares of Stock - marketbeat.com
Rhythm Pharmaceuticals EVP Mazabraud sells $6.6m in stock - Investing.com
Rhythm Pharmaceuticals EVP, Jennifer Lee, sells $8.9m in stock - Investing.com
Rhythm Pharmaceuticals (RYTM) EVP exercises 56,601 options and sells 75,834 shares - Stock Titan
Rhythm Pharmaceuticals (RYTM) EVP sells 57K shares after $6.80 option exercise - Stock Titan
Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript - AOL.com
Dimensional Fund Advisors LP Sells 12,867 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - marketbeat.com
How Investors Are Reacting To Rhythm Pharmaceuticals (RYTM) UK Orphan Expansion For IMCIVREE In Hypothalamic Obesity - Sahm
RYTM (NASDAQ: RYTM) investor plans sale of 5,079 shares worth $597K - Stock Titan
RYTM (RYTM) insider plans Form 144 sale of option and RSU shares - Stock Titan
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Trading the Move, Not the Narrative: (RYTM) Edition - Stock Traders Daily
Rhythm Pharmaceuticals (RYTM) plans 57,000-share stock sale via broker - Stock Titan
Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday? - TradingView
Rhythm Pharmaceuticals at Canaccord Genuity: launch gains widen - Investing.com
Bank of America Corp DE Grows Stake in Rhythm Pharmaceuticals, Inc. $RYTM - marketbeat.com
Rhythm Pharmaceuticals (RYTM) insider outlines 10b5-1 stock sale plan in Form 144 - Stock Titan
Rhythm Pharmaceuticals, Inc. (RYTM) stock price, news, quote and history - Yahoo Finance UK
Rhythm Pharmaceuticals Announces UK MHRA Expansion of IMCIVREE for Acquired Hypothalamic Obesity - Quiver Quantitative
Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury - Yahoo Finance
Analysts Have Conflicting Sentiments on These Healthcare Companies: Orthofix Medical (OFIX), Rhythm Pharmaceuticals (RYTM) and Viatris (VTRS) - The Globe and Mail
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - marketbeat.com
Rhythm Pharmaceuticals (RYTM) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
RHYTHM PHARMACEUTICALS, INC. SEC Filing (Aug 10, 2026) - stocktitan.net
J.P. Morgan Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $146 - Moomoo
Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Analyzing a 22.4% Potential Upside for This Biotech Innovator - DirectorsTalk Interviews
Assenagon Asset Management S.A. Invests $20.71 Million in Rhythm Pharmaceuticals, Inc. $RYTM - marketbeat.com
Rhythm Pharmaceuticals (RYTM) Reports Promising RM 718 Data, Is The Upside Already Priced In? - Sahm
RYTM Maintained by JP Morgan -- Price Target Raised to $146 - GuruFocus
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $146.00 Price Target at JPMorgan Chase & Co. - MarketBeat
The Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - 富途牛牛
California State Teachers Retirement System Acquires 12,269 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Q2 Results And Early RM-718 Obesity Data - Sahm
Citigroup Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $160.00 - MarketBeat
RBC Adjusts Price Target on Rhythm Pharmaceuticals to $155 From $141, Maintains Outperform Rating - Moomoo
Rhythm Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:RYTM) 2026-08-05 - Seeking Alpha
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - The Manila Times
Rhythm Pharmaceuticals reports RM-718 trial results in obesity - Investing.com
Rhythm Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $139.73, Implies 36% Upside - TradingView
Rhythm Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
RHYTHM PHARMACEUTICALS, INC. 2026: Revenue $71.26M, EPS ($0.73) — 10-Q Summary - TradingView
Rhythm Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Issues Quarterly Earnings Results - MarketBeat
Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Call - Benzinga
Rhythm Pharmaceuticals Inc (RYTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):